AS-703026 ≥95%

Supplier: ADIPOGEN CORP MS

Synonyms: (S)-N-(2,3-Dihydroxypropyl)-3-((2-fluoro-4-iodophenyl)amino)isonicotinamide, MSC1936369B, Pimasertib

SYN-1190-M001 SYN-1190-M005 SYN-1190-M010 SYN-1190-M050
102992-672EA 90 USD
102992-672 102992-674 102992-676 102992-678
AS-703026 ≥95%
AS-703026

AS703026 is a novel, selective, non-competitive, orally bioavailable MEK1/2 inhibitor with experimental IC(50) values of 5-11nM. In use on multiple myeloma cells (MM), AS703026 inhibited growth and survival of MM cells and cytokine-induced osteoclast differentiation more potently (~10X) than AZD6244. Inhibition of proliferation induced by AS703026 was mediated by G0-G1 cell cycle arrest and was accompanied by reduction of MAF oncogene expression. AS703026 further induced apoptosis via caspase 3 and Poly ADP ribose polymerase (PARP) cleavage in MM cells, both in the presence or absence of bone marrow stromal cells (BMSCs). Importantly, AS703026 sensitized MM cells to a broad spectrum of conventional (dexamethasone, melphalan), novel or emerging (lenalidomide, perifosine, bortezomib, rapamycin) anti-MM therapies. Significant tumour growth reduction in AS703026- vs. vehicle-treated mice bearing H929 MM xenograft tumours correlated with downregulated pERK1/2, induced PARP cleavage, and decreased microvessels in vivo. Moreover, AS703026 (200nM) was cytotoxic against the majority of tumour cells tested from patients with relapsed and refractory MM (84%), regardless of mutational status of RAS and BRAF genes. Importantly, BMSC-induced viability of MM patient cells was similarly blocked within the same dose range.

Formula: C₁₅H₁₅FIN₃O₃
MW: 431.2 g/mol
Storage Temperature: Refrigerator
MDL Number: MFCD16660676
CAS Number: 1236699-92-5

Order Now

Specification Test Results

Purity 95%
Appearance/Color Solid.
Solubility Soluble in DMSO. Slightly soluble (1mg/ml) in ethanol.

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR